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Abstract
The in vivo hollow fiber assay, in which semipermeable
hollow fibers filled with tumor cells, are implanted into
animals, was originally developed to screen for anti-
cancer compounds before assessment inmore complex
tumor models. To enhance screening and evaluation of
anticancer drugs, we have applied optical imaging tech-
nology to this assay. To demonstrate that tumor cells
insidehollowfiberscancommunicatewith thehostmice,
we have used fluorescence imaging in vivo and CD31
immunostaining ex vivo to show that angiogenesis oc-
curs aroundcell-filled hollow fibers by 2weeks after sub-
cutaneous implantation. Bioluminescence imaging has
been used to follow the number of luciferase-expressing
tumor cells within implanted hollow fibers; proliferation
of those cells was found to be significantly inhibited
by docetaxel and irinotecan. We also used biolumines-
cence imaging of hollow fibers to monitor the nuclear
factor KB (NFKB) pathway in vivo; NFKB activation by
lipopolysaccharide and tumor necrosis factor-A was
evaluated in tumor cell lines genetically engineered to
express luciferase controlled by an NFKB-responsive
element. These results demonstrate that optical imaging
of hollow fibers containing reporter tumor cells can be
used for the rapid and accurate evaluation of antitumor
activities of anticancer drugs and for measurement of
molecular pathways.
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Introduction
A recurrent challenge in the drug discovery of chemother-
apeutic agents is to expedite the in vivo evaluation of in vitro
leads (i.e., to investigate whether a compound capable of
inhibiting tumor growth or acting on a target in vitro will also
do so in vivo). The initial in vivo evaluation of compounds
that show in vitro activity against tumor cell lines has tra-
ditionally involved transplanting these cells into immuno-
compromised host animals and then measuring the size of
developing tumors in the presence and in the absence of
the test agent. This valuable method is well-established
and allows interactions between tumor cells and host ani-
mals to occur. Measurement of subcutaneous tumor size by
external calipers is noninvasive; therefore, longitudinal studies
are possible, but it takes some time for tumors to grow to the
point that they become palpable without sacrificing animals. In
addition, some cell lines, although derived from human tumors,
are not tumorigenic in animal models, limiting the utility of this
traditional xenograft method in studying the effects of chemo-
therapeutic agents on these cell lines in vivo.
Recently, tumor cell lines have been genetically engineered
with constitutive bioluminescent (i.e., firefly luciferase) or fluo-
rescent (i.e., green fluorescent protein or Ds-Red) reporter
vectors; with the parallel development of instrumentation for
optical imaging of live animals, it is now possible to assess the
size of developing tumor xenografts before they reach a size
sufficient to become palpable. In a further refinement of this
approach, by replacing the constitutive promoter for an optical
reporter with a responsive element of certain transcriptional
factors (e.g. p53, E2F, or hypoxia-inducible factors) [1–4], it
becomes possible to monitor a particular pathway or process
regulated by a transcriptional factor. It is also possible to
genetically reengineer bioluminescent or fluorescent proteins
themselves (e.g., as fusion proteins) to respond to specific
molecular process. This approach has been used to make
reporters that respond to proteasome inhibition [5], to phos-
phorylation by particular kinases [6], or to cleavage by specific
proteases such as caspases [7]. Such reporters have greatly
enhanced our ability to use noninvasive molecular imaging to
monitor the contribution of molecular pathways to tumorigene-
sis and tumor progression.
The in vivo hollow fiber assay was developed by Hollings-
head et al. [8] at the National Cancer Institute as a tool for the
preliminary screening of novel anticancer drugs before assess-
ment in more complex tumor models. In this assay, semiper-
meable hollow fibers filled with tumor cells are implanted into
the subcutaneous or intraperitoneal compartments of host
mice. The mice are then treated with novel compounds to
evaluate the in vivo activity of these compounds and their
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potential to inhibit cell growth in vivo. Hollow fibers are re-
trievable for subsequent assessment of cell viability (MTT
assay) [9], flow cytometry [10], histology [11], and/orWestern
blot analysis [12]. The hollow fiber assay was not meant to
replace classic xenograft systems, in part because it does
not model the complex interactions and phenomena that
occur when tumor cells grow in and interact with normal host
tissues. However, in comparison with a traditional tumor
xenograft model, the hollow fiber assay does offer several
advantages: 1) it allows retrieval of tumor cells uncontami-
nated by host cells for subsequent analysis; 2) it permits
shortened evaluation time and, therefore, reduced consump-
tion of test compounds; 3) there is no significant change in
the volume of the implant or in the weight of the animal; 4)
there is no limitation on cell type (nontumorigenic cells can be
evaluated); and 5) it allows for multiplexing (several hollow
fibers, each filled with a different cell type, can be implanted
in one animal, and the in vivo effects of a test compound on
these cell types can be evaluated in simultaneously) [1].
Unlike the xenograft model, tumor cells are separated from
surrounding tissues by a semipermeable fiber wall, limiting
the complex interaction between tumor cells and host tis-
sues, and the growth of tumor cells is limited by the geomet-
ric constraint of the fibers. In addition, implantation of hollow
fibers requires minimally invasive surgery.
In an effort to establish a screening method that will allow
a rapid and accurate evaluation of anticancer drugs in ani-
mals, we have attempted to leverage the advantages of the
in vivo hollow fiber model and the in vivo imaging of cell lines
genetically engineered with optical reporters by integrating
these two approaches. We here show that tumor cells inside
semipermeable hollow fibers do communicate with and af-
fect surrounding host tissues, that the effect of antitumor
agents on tumor cells within an implanted hollow fiber can be
rapidly assessed after administration to host animals, and
that activation of specific signaling pathways can be studied
in vivo in tumor cells within an implanted hollow fiber. We
expect that this approach will shorten the time for the val-
idation of drug targets in living animals before assessment in
more complex tumor models (e.g., metastatic mouse mod-
els, transgenic mouse models).
Materials and Methods
Chemicals and Reagents
Human recombinant tumor necrosis factor-a (TNF-a) and
lipopolysaccharide (LPS; Escherichia coli serotype 055)
were purchased from Sigma (St. Louis, MO). Both TNF-a
and LPS were dissolved in distilled water (20 mg/ml and
1.5 mg/ml, respectively) and stored at 20jC. D-Luciferin
(Xenogen, Alameda, CA) was dissolved in phosphate-
buffered saline (PBS) (15 mg/ml) and stored at 20jC.
Docetaxel (Taxotere; Aventis, Bridgewater, NJ) was diluted
with an entire diluent supplied by the manufacturer to obtain
a 10-mg/ml solution andwas stored at room temperature. Irino-
tecan hydrochloride (Camptosar, 20 mg/ml; Pharmacia and
Upjohn Co., New York, NY) was stored at room temperature.
Cell Culture and Transfection
MAT B III rat mammary adenocarcinoma cells were
maintained in McCoy’s 5A medium supplemented with 10%
fetal bovine serum (FBS), and MCF7 human breast cancer
cells were maintained in Dulbecco’s modified Eagle’s me-
dium supplemented with 10% FBS. Plasmid transfection
was performed in 10-cm tissue culture plates with Lipofecta-
mine 2000 (Invitrogen, Carlsbad, CA). To make stable cell
lines, cells were cotransfected with 5 mg of pGL3-control
(Promega, Madison, WI) or pTL-NFnB (Panomics, Redwood
City, CA) and 0.5 mg of empty pcDNA3 (Invitrogen). Twenty-
four hours later, transfected cells were selected and main-
tained in a medium containing G418 (1 mg/ml). Single clones
of transfected cells were established by single cell deposi-
tion (manuscript in preparation). The clonesMATB III-Luc- 3H9
and MCF7-Luc-10C11 were characterized as exhibiting a high
expression of luciferase.
Preparation and Implantation of Hollow Fibers
Polyvinylidene fluoride (PVDF) hollow fibers were pur-
chased from Spectrum Laboratories, Inc. (Rancho Dominguez,
CA). Encapsulation of cells in hollow fibers was performed as
described before [13]. Briefly, a hollow fiber (o.d. = 1.2 mm; i.d.
= 1 mm; molecular mass cutoff = 500 kDa) was filled with cells
and sealed in 1.5-cm segments with a heat sealer (Outsource
2000, Albertville, AL). A long fiber was subsequently cut at the
sealed portion separating the segments. The 1.5-cm sealed
fibers were then cultivated in six-well culture plates for 24 hours
before implantation into nude mice: nu/nu nude mice (Charles
River, Wilmington, MA) were anesthetized by intraperitoneal
administration of ketamine (140 mg/kg) and xylazine (12 mg/
kg). The 1.5-cm sealed hollow fiber segments filled with tumor
cells were finally implanted subcutaneously using an 11-gauge
trocar inserted through a neck incision. All animal studies de-
scribed in this study were approved by the Merck Research
Laboratories Institutional Animal Care and Use Committee.
Subcutaneous Tumor Xenograft
MAT B III rat mammary tumor cells were trypsinized and
resuspended in PBS at a concentration of 107 cells/ml. A
total of 106 cells in 100 ml of PBS was subcutaneously in-
jected into each flank of anesthetized nude mice. Tumor size
was calculated using caliper measurements with the equa-
tion: (length  width2)/2.
Fluorescence Imaging of Angiogenesis
AngioSense750 probe (VisEn Medical, Inc., Woburn, MA)
is a blood pool probe based on a near-infrared fluorochrome-
labeled long circulating synthetic graft copolymer. This fluo-
rescent probe allows localization of the vasculature for
extended periods of time and for tracking of angiogenesis.
To detect angiogenesis in nude mice bearing hollow fibers,
2 nmol of AngioSense750 in 150 ml of PBS per mouse was
administered by tail vein injection. Twenty-four hours later,
fluorescence imaging was acquired with an acquisition time
of 4 seconds, an excitation wavelength in the range of 710 to
Optical Imaging of Hollow Fibers Zhang et al. 653
Neoplasia . Vol. 9, No. 8, 2007
760 nm, and an emission wavelength in the range of 810 to
870 nm, using the IVIS200 imaging system (Xenogen).
Immunohistochemistry
CD31 expression was immunohistochemically assessed
in three mice from each group of mice harboring hollow fibers
(with or without tumor cells). Hollow fibers and surrounding
tissues were dissected and immersed in zinc–Tris fixative
(BD Pharmingen, San Diego, CA) for 24 hours. Six equally
spaced sections were processed to cover the entire length of
the fibers. Five-micron paraffin-embedded sections were
incubated with rat anti-mouse CD31 monoclonal antibody
(clone MEC13.3; BD Pharmingen). Subsequently, sections
were incubated with biotinylated polyclonal goat anti-rat IgG
(mouse adsorbed) and streptavidin–horseradish peroxi-
dase. The substrate 3,3V-diaminobenzidine tetrahydrochlo-
ride was used to detect CD31 immunoreactivity. Finally, the
sectionswere counterstainedwithMayer’s hematoxylin.Omis-
sion of the primary antibody served as a negative control.
Bioluminescence Imaging of Hollow Fibers
For in vitro studies, D-luciferin was added to a tissue cul-
ture medium in plates containing cell-filled hollow fibers up to
a final concentration of 50 mg/ml. Five minutes later, photons
were counted using the IVIS200 imaging system (Xenogen)
according to the manufacturer’s instructions. Data were an-
alyzed using LivingImage software (version 2.50.1; Xeno-
gen). Bioluminescence intensities from manually selected
region(s) of interest (ROI) were calculated, and data were
expressed as total flux (photons/sec). For evaluation of
anticancer drugs, nude mice bearing hollow fibers filled with
MAT B III-Luc-3H9 or MCF7-Luc-10C11 cells were treated
with Taxotere (20 mg/kg) or Camptosar (100 mg/kg) for three
doses, with a 4-day interval between doses. Longitudinal
imaging was acquired with an acquisition time of 5 minutes at
15 minutes after the administration of D-luciferin (90 mg/kg,
i.p.), and photons were analyzed as above. To investigate
nuclear factor nB (NFnB) activation in vivo, nude mice bear-
ing hollow fibers filled with MAT B III-NFnB cells were
administered LPS (2 mg/kg, i.p.) or TNF-a (2 mg/mouse,
i.p.). Before and after the administration of LPS or TNF-a,
bioluminescence imaging was obtained after D-luciferin in-
jection; photons were counted and analyzed as above.
Results
Kinetics of Luciferase Imaging in Hollow Fiber Models
To determine the time range in which a luciferase signal is
at a maximum, nude mice were implanted with hollow fibers
filled with MCF7-Luc-10C11 cells. Twenty-four hours after
fiber implantation, sequential bioluminescent images of these
mice were acquired with an acquisition time of 5 minutes at
5-minute intervals (with no delay time) after luciferin admin-
istration. By 20 minutes, a strong bioluminescence signal
was observed, which continued to increase up to about
40 minutes. A maximum in the bioluminescence signal was
detected between 40 and 45 minutes and decreased gradu-
ally thereafter (Figure 1, A and B). A similar kinetic profile
was observed when using MAT B III-Luc-3H9 cells. There-
fore, in subsequent studies with implanted hollow fibers,
in vivo bioluminescence imaging was acquired about 40 to
45 minutes after luciferin administration.
Proliferation of Tumor Cells in Hollow Fibers In Vitro
and In Vivo
To measure the proliferation of tumor cells in hollow
fibers in vitro, MAT B III-Luc-3H9 cells in hollow fibers were
cultivated in six-well tissue culture plates. Bioluminescent
images were acquired with a 5-minute acquisition time after
the addition of luciferin to the medium at a final concentration
of 15 mg/ml. A significant linear correlation between biolumi-
nescence and cell number was observed in hollow fibers
cultivated in six-well tissue culture plates (data not shown).
Furthermore, in nude mice implanted with cell-filled fibers, a
linear correlation between bioluminescent signal and cell
number was observed (Figure 2, A and B). Longitudinal bio-
luminescence images demonstrated that bioluminescence
decreased by about 30% during the first 24 hours after the
implantation of hollow fibers, and then increased at later
time points (Figure 2C). By 1 week after implantation into
mice, in vivo bioluminescence imaging indicated that tumor
cells in hollow fibers had proliferated rapidly (Figure 2D).
The proliferation of tumor cells within hollow fibers, deter-
mined by bioluminescence, was compared to tumor growth
in the xenograft model, determined by caliper measurement.
With this cell line, bioluminescent signals may be used to
monitor the growth of tumor cells within 10 days of the
implantation of hollow fibers, at which time tumors have not
yet developed to the point where they are detectable by
caliper measurement.
Angiogenesis Associated with Hollow Fibers
Although the hollow fiber assay does not model the com-
plex interactions and phenomena that occur when tumor
cells are grown in normal host tissues, some interactions do
take place. To investigate one such interaction, we attempted
to detect angiogenesis in tissues adjacent to hollow fibers.
Hollow fibers filled with either MAT B III-Luc-3H9 cells or with
medium only were implanted in both flanks of two groups of
nude mice. AngioSense750, a near-infrared labeled copoly-
mer that localizes in the vasculature, was administered by
intravenous injection to nude mice harboring hollow fibers,
and fluorescent images were acquired. Starting from day 6
after hollow fiber implantation, fluorescent signals derived
from AngioSense750 were detected in both groups of mice
(with or without MAT B III-Luc-3H9 cells) (Figure 3A). There-
after, fluorescent signals from the area around hollow fibers
without tumor cells dropped rapidly to baseline, whereas
signals from the area around hollow fibers containing MAT B
III-Luc-3H9 cells remained stable for another week and in-
creased from that time until the end of the study (Figure 3, A
and B). To confirm the angiogenesis detected by in vivo
imaging, immunohistochemical staining of tissue sections,
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including hollow fibers, was also performed with antibodies
to CD31 (a marker for endothelial cells, which predominate in
neovascular tissues) [14]. Strong CD31 immunoreactivity
was detected outside hollow fibers that contained tumor
cells, but no immunoreactivity was detected adjacent to hol-
low fibers without tumor cells (except that some immunore-
activity was observed in sweat glands; Figure 3C).
In Vivo Inhibition of Tumor Cell Growth in Hollow Fibers
By Anticancer Drugs
To assess the ability of the in vivo hollow fiber/optical
reporter cell line model to report antitumor activities of known
anticancer drugs, two commercial drugs chosen for their
different mechanisms of action (Taxotere and Camptosar)
were selected. For the first study, hollow fibers filled with
MAT B III-Luc-3H9 cells were implanted into each flank of
nude mice. Mice were divided into three groups with three
mice in each group, and each group was treated either with a
vehicle (control) or with Taxotere (20 mg/kg) or Camptosar
(100 mg/kg) at 4-day intervals starting on day 8 after the
implantation of hollow fibers. The results show that tumor cell
proliferation was inhibited by both Taxotere and Camptosar
(Figure 4A). Moreover, by day 12 after the initial dose, tumor
cell numbers had decreased by about 50%, as detected by
bioluminescence imaging. In a second study, nude mice har-
boring hollow fibers filled with MCF7-Luc-10C11, an estro-
gen receptor–positive human breast cancer cell line stably
expressing luciferase, were also treated with Taxotere or
Camptosar as above. As in the case of MAT B III cells, both
Taxotere and Camptosar significantly inhibited the prolifera-
tion of MCF7 cells (Figure 4, B and C).
NFjB Induction in Hollow Fibers In Vivo
To assess the ability of the in vivo hollow fiber/optical
reporter cell line model to report pathway-specific effects of
administered compounds, cells reporting the activity of the
transcription factor NFnB were constructed. NFnB plays an
important role in tumor development and progression. NFnB
and the signaling pathways involved in its activation are,
therefore, attractive targets for cancer prevention and ther-
apeutics. Thus, a cell line expressing an optical reporter to
monitor NFnB activity is expected to be a powerful tool for
the target validation of anticancer drugs that affect the
NFnB pathway. To investigate whether NFnB induction can
be imaged in the hollow fiber model, LPS was administrated
intraperitoneally into nude mice harboring hollow fibers filled
with MAT B III-NFnB-Luc cells—a cell line stably transfected
with luciferase driven by an NFnB-responsive element.
Figure 1. Kinetics of luciferase imaging. Hollow fibers filled with MCF7-Luc-10C11 cells stably expressing luciferase at 5  106 cells/ml (60,000 cells/fiber) were
implanted into nude mice in both flanks. (A) Twenty-four hours later, sequential bioluminescence images were acquired at 5-minute intervals after luciferin
administration (90 mg/kg, i.p.). (B) Quantitative analysis of sequential images expressed as photons per second. Each time point represents 10 hollow fibers
implanted from five mice (error bars represent the standard error of the mean).
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When compared to imaging before the administration of
LPS, bioluminescence from NFnB reporter cells was signif-
icantly increased after LPS administration. NFnB activity was
increased four-fold between 6 and 8 hours after treatment
with LPS, whereas NFnB activity dropped significantly after
24 hours (Figure 5, A and B). To provide additional verifica-
tion that this optical reporter is an appropriate indicator of
NFnB activation, TNF-a was administered intraperitoneally
(2 mg/mouse). As observed with LPS, TNF-a increased NFnB
reporter activity in hollow fibers in vivo, and this increase reached
a maximum at 8 hours after TNF-a injection (Figure 5C).
Discussion
The original hollow fiber assay involves the short-term in vitro
cultivation of cells, followed by in vivo implantation into nude
mice for short-term evaluation of drug efficacy. However, for
a longitudinal study, this method requires the retrieval of
hollow fibers at each time point from euthanized mice. Our
observations have expanded the application of this assay
by combining it with optical imaging, providing a longitudinal
noninvasive method to evaluate tumor cell growth in hollow
fibers in vivo.
Optical imaging of hollow fiber allows medium-term (sev-
eral weeks) evaluation of anticancer drugs. In comparison
with the kinetics of bioluminescence in the previous study
[15], the delayed kinetics observed in this study might
be explained by the lower dose of luciferin injected (90 vs
150 mg/kg), smaller cell numbers implanted inside hollow
fibers (24,000 vs 1  106 cells), and/or different tumor types
(mammary versus brain tumors). The proliferation of tumor
cells (MAT B III and MCF7 were tested) was followed for at
least 4 weeks by noninvasive imaging in this study. Biolu-
minescence imaging has demonstrated that tumor cells are
able to proliferate actively for at least 4 weeks within hollow
fibers. Thereafter, tumor cells grow slowly or cease prolifer-
ating, and bioluminescence shows a decrease in cell num-
ber. Unlike the tumor xenograft model, in which tumor cells
are able to invade surrounding tissues and to proliferate
without limit [16], the growth inhibition seen in hollow fibers
is presumably caused by contact inhibition due to constraints
in the internal volume of the hollow fiber model. As tumor cell
Figure 2. Proliferation of MAT B III-Luc-3H9 cells determined by bioluminescence imaging in hollow fibers. (A) Bioluminescence imaging of nude mice harboring
hollow fibers filled with indicated numbers of MAT B III-Luc-3H9 cells per fiber. (B) Linear correlation between bioluminescence and the numbers of cells implanted.
(C) Longitudinal bioluminescence imaging of a representative mouse was acquired on the days indicated after hollow fiber implantation. (D) Mean bioluminescent
flux (photons/sec) was obtained from 10 hollow fibers in five mice (each bearing two hollow fibers; blue line), and mean tumor volume was determined with caliper
measurement in a tumor xenograft (mean from 10 tumors in five mice; red line) (error bars represent the standard error of the mean).
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Figure 3. Detection of angiogenesis around hollow fibers. (A) Fluorescent images acquired 24 hours after the intravenous administration of AngioSense750 into
nude mice harboring hollow fibers without tumor cells (upper panel, ROI encircled) and with MAT B III-Luc-3H9 tumor cells (24,000 cells/fiber; lower panel, ROI
encircled). (B) Average fluorescence imaging (photons/sec) was calculated from six hollow fibers in three mice (error bars represent the standard error of the
mean). (C) CD31 immunohistochemical staining in hollow fiber sections on day 28 (upper panel, no tumor cells; lower panel, with tumor cells). Magnification is
shown on the lower left corner.
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Figure 4. Inhibition of the proliferation of mammary adenocarcinoma cells in hollow fibers in vivo by Taxotere and Camptosar. Nude mice bearing hollow fibers
were either vehicle-treated or treated with Taxotere (20 mg/kg) or Camptosar (100 mg/kg) at indicated times (at 4-day intervals; arrowheads) after the implantation
of hollow fibers filled with MAT B III-Luc-3H9 (A) or MCF7-Luc-10C11 (C) cells. Bioluminescence imaging was acquired longitudinally in these mice over the period
shown. Data points show the means of six hollow fibers from three mice (each bearing two hollow fibers; error bars represent the standard error of the mean). (B)
Longitudinal bioluminescence imaging of a representative mouse with either vehicle treatment (upper panel) or Taxotere treatment (lower panel) on days 15, 19
and 23, which harbors hollow fibers filled with MCF7-Luc-10C11 cells, was acquired on the days indicated after hollow fiber implantation.
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proliferation within hollow fibers can be tracked for at least
4 weeks, a broad time window to evaluate anticancer drugs
is ensured in this model.
Over this time period, the communication of tumor cells
within hollow fibers with host tissues is strongly supported
by the finding that angiogenesis is detected in tissues sur-
rounding hollow fibers. Angiogenesis around hollow fibers is
significantly associated with the presence of tumor cells,
suggesting that there is an interaction between tumor cells,
even though they are constrained within hollow fibers, and
surrounding host cells. The angiogenesis detected in both
groups of mice shortly after fiber implantation is most likely
due to healing from a minimally invasive surgery when
hollow fibers were implanted. The significant difference in
Figure 5. Induction of NFjB reporter in hollow fibers in vivo by LPS and TNF-a. (A) Bioluminescence imaging of a representative mouse on pretreatment and
posttreatment with LPS. (B and C) Nude mice harboring hollow fibers with MAT B III-NFjB-Luc cells were administered LPS (B; 2 mg/kg, i.p.) or TNF-a (C; 2 g/
mouse, i.p.). Bioluminescent images were acquired immediately before the administration of LPS or TNF-a, as well as at the indicated time after the administration
of an antitumor agent. Data points show a mean bioluminescent flux (photons/sec) of six hollow fibers from three mice (each bearing two hollow fibers; error bars
represent the standard error of the mean).
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AngioSense750 fluorescent signals between hollow fibers
with or without tumor cells strongly suggests that angio-
genesis is stimulated by tumor cells within hollow fibers.
Our results support previous histologic studies that found
that angiogenesis occurs around hollow fibers [17]. Com-
pared to studies using postmortem histologic study as the
primary end point, our approach using AngioSense750 is
noninvasive; therefore, results can be obtained longitudinally
with a small number of animals. Taken together, we have con-
firmed that communication and interaction occur between
tumor cells inside hollow fibers and the host mice. For ex-
ample, tumor cells may secrete positive angiogenic factors,
such as vascular endothelial growth factor, platelet-derived
growth factor, and insulin-like growth factor, that freely dif-
fuse out of the fibers into surrounding tissues and promote
the development of new vessels [18]. This angiogenesis
around hollow fibers increases the supply of oxygen and
nutrients to maintain the growth and proliferation of tumor
cells inside the fibers.
The hollow fiber in vivo imaging model allows the rapid
and accurate evaluation of the antitumor activities of novel
anticancer drugs. In comparison with the tumor xenograft
model, tumor cell proliferation on the days soon after fiber
implantation was detected with noninvasive biolumines-
cence imaging, suggesting its rationale for early administra-
tion of anticancer drugs. In the present study, two known
anticancer drugs in clinical use (Taxotere and Camptosar)
were evaluated in the hollow fiber model with different tumor
cell lines. Taxotere is a microtubule-stabilizing taxane, which
binds to free tubulin and promotes the assembly of tubulin
into stable microtubules while simultaneously inhibiting their
disassembly. This leads to the stabilization of microtubules,
which results in apoptosis through mitotic catastrophe in
breast cancer cells [19]. The active metabolite of Camptosar,
SN-38, inhibits topoisomerase I activity, resulting in DNA
double-strand breaks and, ultimately, apoptosis [20]. Admin-
istration of Camptosar has been shown to induce antitumor
activity in human tumor xenografts in mice [21]. In both cell
lines tested, Taxotere and Camptosar significantly inhibited
the proliferation of tumor cells within 4 days of their admin-
istration. Thus, the proof of concept is well-established, and
this model is suitable for evaluating novel anticancer drugs.
In addition, as these PVDF hollow fibers have a 500-kDa
cutoff, this technology can potentially be used to evaluate
antibody (Peter Lassota, Caliper, Inc., personal communica-
tion) and siRNA therapies, in addition to small molecules.
Hollow fiber technology is applicable not only to the eval-
uation of drug efficacy but also to the study of intracellular
molecular pathways. For example, in a previous study [6],
a p27-luciferase–expressing tumor cell was used to monitor
Cdk2 activity by in vivo bioluminescence imaging in hollow
fibers. To further illustrate the utility of this technology in study-
ing specific molecular pathways, we have evaluated NFnB
signaling in the present study. NFnB is the most important
component of the signaling pathway activated by inflamma-
tion and infection [22]. Activation of NFnB in inflammatory
cells in response to infectious agents, inflammatory cyto-
kines, and proteins, and danger signals released by necrotic
cells lead to the production of secreted factors that enhance
the growth, survival, and vascularization of carcinoma cells
[22]. In the present study, a luciferase plasmid driven by an
NFnB-responsive element was stably transfected into tumor
cells, and the resultant reporter cell line was then evaluated
in the hollow fiber model after treatment of the host mice
with either LPS or TNF-a. Consistent with the data obtained
in vitro, TNF-a and LPS activated the NFnB pathway and
induced the NFnB reporter. In comparison with a transgenic
mouse model, in which NFnB activity was monitored in
normal mouse tissues [23], the hollow fiber model described
here is capable of providing a rapid evaluation of NFnB
activity in both human and mouse/rat tumor cells. Thus, the
model presented here can be used to test NFnB inhibitors
(small molecule compounds and peptides) under develop-
ment by pharmaceutical companies. Based on the above
results, if a cell line is genetically engineered with a pathway-
dependent optical reporter, it could be used in the hollow fiber
model to monitor molecular pathways or events.
In summary, the technology of the in vivo imaging of hol-
low fibers containing tumor cells expressing optical reporters
has been applied to the evaluation of antitumor activities of
known anticancer drugs in nude mice and can be used in
the near future for primary anticancer drug screening in vivo.
This technology allows an early evaluation of anticancer
drugs because it is not necessary to wait for palpable tumor
formation, and it also permits the retrieval of uncontaminated
tumor cells for additional analysis. There is no limitation on
cell type; even nontumorigenic tumor cells can be used in
this model. The use of genetically engineered constitutively
expressed optical reporters affords the ability to noninva-
sively and repetitively image implanted hollow fibers contain-
ing tumor cells, enabling longitudinal studies to follow the
in vivo antitumor activity of a compound in the same group of
mice. Furthermore, with the use of more sophisticated ge-
netically engineered optical reporters, this technology can be
applied to monitor specific molecular events and pathways
(e.g., apoptosis, cell proliferation, and cell cycle change). In
particular, implantation of multiple fibers (each bearing one
pathway-specific reporter cell line) will allow investigators to
image multiple molecular pathways in one mouse, permitting
the determination of whether compounds of interest target
one pathway/molecule but not the others.
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